147 related articles for article (PubMed ID: 35844046)
21. Infectivity of hepatic allografts with antibodies to hepatitis B virus.
Dodson SF; Issa S; Araya V; Gayowski T; Pinna A; Eghtesad B; Iwatsuki S; Montalvo E; Rakela J; Fung JJ
Transplantation; 1997 Dec; 64(11):1582-4. PubMed ID: 9415560
[TBL] [Abstract][Full Text] [Related]
22. Liver transplantation from hepatitis B surface antigen-positive donors.
Saidi RF; Jabbour N; Shah SA; Li YF; Bozorgzadeh A
Transplant Proc; 2013; 45(1):279-80. PubMed ID: 23267801
[TBL] [Abstract][Full Text] [Related]
23. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis.
Wong TC; Fung JY; Cui TY; Lam AH; Dai JW; Chan AC; Cheung TT; Chok KS; Ng KK; Lo CM
J Hepatol; 2019 Jun; 70(6):1114-1122. PubMed ID: 30871981
[TBL] [Abstract][Full Text] [Related]
24. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study.
Chancharoenthana W; Townamchai N; Pongpirul K; Kittiskulnam P; Leelahavanichkul A; Avihingsanon Y; Suankratay C; Wattanatorn S; Kittikowit W; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Am J Transplant; 2014 Dec; 14(12):2814-20. PubMed ID: 25395260
[TBL] [Abstract][Full Text] [Related]
25. Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients--5-year single-center experience.
Brandl A; Stolzlechner P; Eschertzhuber S; Aigner F; Weiss S; Vogel W; Krannich A; Neururer S; Pratschke J; Graziadei I; Öllinger R
Transpl Int; 2016 Apr; 29(4):471-82. PubMed ID: 26716608
[TBL] [Abstract][Full Text] [Related]
26. Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients.
Wang XD; Feng SJ; Liu JP; Song TR; Huang ZL; Fan Y; Shi YY; Chen LY; Lv YH; Xu ZL; Li XH; Wang L; Lin T
BMC Infect Dis; 2021 Jan; 21(1):41. PubMed ID: 33422017
[TBL] [Abstract][Full Text] [Related]
27. Risk factors of de novo hepatitis B virus infection in pediatric hepatitis B core antibody positive liver graft recipients under prophylactic therapy.
Dong C; Song Z; Chen J; Ma N; Meng X; Sun C; Duan K; Bi B; Wang K; Qin H; Han C; Yang Y; Zhang F; Zheng W; Gao W
J Gastroenterol Hepatol; 2020 May; 35(5):827-832. PubMed ID: 31609494
[TBL] [Abstract][Full Text] [Related]
28. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.
Nery JR; Nery-Avila C; Reddy KR; Cirocco R; Weppler D; Levi DM; Nishida S; Madariaga J; Kato T; Ruiz P; Schiff E; Tzakis AG
Transplantation; 2003 Apr; 75(8):1179-86. PubMed ID: 12717200
[TBL] [Abstract][Full Text] [Related]
29. Donor derived hepatitis B virus infection: Analysis of the Organ Procurement & Transplantation Network/United Network for Organ Sharing Ad Hoc Disease Transmission Advisory Committee.
Theodoropoulos NM; La Hoz RM; Wolfe C; Vece G; Bag R; Berry GJ; Bucio J; Danziger-Isakov L; Florescu DF; Goldberg D; Ho CS; Lilly K; Malinis M; Mehta AK; Nalesnik MA; Sawyer R; Strasfeld L; Wood RP; Michaels MG
Transpl Infect Dis; 2021 Feb; 23(1):e13458. PubMed ID: 32894634
[TBL] [Abstract][Full Text] [Related]
30. Use of grafts from anti-HBc-positive donors in liver transplantation: a 5-year, single-center experience.
Bortoluzzi I; Gambato M; Albertoni L; Mescoli C; Pacenti M; Cusinato R; Germani G; Senzolo M; Rugge M; Boccagni P; Zanus G; Cillo U; Burra P; Russo FP
Transplant Proc; 2013 Sep; 45(7):2707-10. PubMed ID: 24034028
[TBL] [Abstract][Full Text] [Related]
31. Octogenarian liver grafts: Is their use for transplant currently justified?
Jiménez-Romero C; Cambra F; Caso O; Manrique A; Calvo J; Marcacuzco A; Rioja P; Lora D; Justo I
World J Gastroenterol; 2017 May; 23(17):3099-3110. PubMed ID: 28533667
[TBL] [Abstract][Full Text] [Related]
32. HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive liver-grafts to HBV-naïve recipients: A retrospective study.
Hornuss D; Rudi A; Koerner L; Mohr I; Merle U; Wehling C; Rupp C; Dill MT; Golriz M; Schnitzler P; Brenner T; Mehrabi A; Weiss KH; Mieth M
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101496. PubMed ID: 33740476
[TBL] [Abstract][Full Text] [Related]
33. Liver grafts from anti-hepatitis B core positive donors: a systematic review.
Cholongitas E; Papatheodoridis GV; Burroughs AK
J Hepatol; 2010 Feb; 52(2):272-9. PubMed ID: 20034693
[TBL] [Abstract][Full Text] [Related]
34. Expanding the Donor Pool: First Use of Hepatitis B Virus Nat Positive Solid Organ Allografts Into Seronegative Recipients.
Delman AM; Turner KM; Safdar K; Anwar N; Silski LS; Lee TC; Luckett K; Cuffy MC; Quillin RC; Schoech M; Kaiser TE; Govil A; Bari K; Shah SA
Ann Surg; 2021 Oct; 274(4):556-564. PubMed ID: 34506310
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic Strategy Against De Novo Hepatitis B Virus Infection for Pediatric Recipients Who Receive Hepatitis B Core Antibody-Positive Liver Grafts.
Song Z; Dong C; Meng X; Sun C; Wang K; Qin H; Han C; Yang Y; Zhang F; Zheng W; Chen J; Duan K; Bi B; Gao W
Liver Transpl; 2021 Jan; 27(1):96-105. PubMed ID: 32511854
[TBL] [Abstract][Full Text] [Related]
36. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
[TBL] [Abstract][Full Text] [Related]
37. Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg-positive donors to HBsAg-negative recipients.
Yin S; Wu L; Zhang F; Huang X; Wu J; Wang X; Lin T
Liver Int; 2023 Nov; 43(11):2415-2424. PubMed ID: 37592870
[TBL] [Abstract][Full Text] [Related]
38. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool.
Donataccio D; Roggen F; De Reyck C; Verbaandert C; Bodeus M; Lerut J
Transpl Int; 2006 Jan; 19(1):38-43. PubMed ID: 16359375
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
40. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease.
Madayag RM; Johnson LB; Bartlett ST; Schweitzer EJ; Constantine NT; McCarter RJ; Kuo PC; Keay S; Oldach DW
Transplantation; 1997 Dec; 64(12):1781-6. PubMed ID: 9422420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
